Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Chemistry

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors are increasingly studied for targeted cancer therapy.
• Radiolabeling PARP inhibitors with radionuclides offers a novel approach for radionuclide therapy.
• Significant research is ongoing to optimize these agents for clinical application.

Purpose of the Study:

• To review current advancements in radiolabeled PARP inhibitors for targeted radionuclide therapy.
• To focus on the selection and radiobiological properties of radionuclides used.
• To explore biomarkers and dosimetry for future development.

Main Methods:

• Literature review of recent studies on radiolabeled PARP inhibitors.
• Analysis of radionuclide selection criteria and their biological impact.
• Examination of biomarkers and dosimetry relevant to targeted radionuclide therapy.

Main Results:

• Radiolabeled PARP inhibitors demonstrate potential for selective cancer cell killing.
• Different radionuclides exhibit varying efficacy and safety profiles.
• Biomarkers and dosimetry are crucial for optimizing treatment efficacy and minimizing toxicity.

Conclusions:

• Radiolabeled PARP inhibitors represent a promising strategy in targeted radionuclide therapy.
• Careful selection of radionuclides and understanding of biomarkers are key to successful application.
• Further research in dosimetry and clinical translation is warranted.